Mitchell MS - Search Results

1

Phase I trial of a 5-day course of carbetimer.

Grunberg SM, Ehler E, Francis RB Jr, Mitchell MS. Grunberg SM, et al. Among authors: mitchell ms. Invest New Drugs. 1990;8 Suppl 1:S41-9. doi: 10.1007/BF00171983. Invest New Drugs. 1990. PMID: 2380016

2

Phase II trial of carbetimer in metastatic melanoma.

Quan WD Jr, Mitchell MS. Quan WD Jr, et al. Among authors: mitchell ms. Invest New Drugs. 1993 May-Aug;11(2-3):231-3. doi: 10.1007/BF00874162. Invest New Drugs. 1993. PMID: 8262738 Clinical Trial.

3

Phase I study of recombinant beta-interferon given by four-hour infusion.

Grunberg SM, Kempf RA, Venturi CL, Mitchell MS. Grunberg SM, et al. Among authors: mitchell ms. Cancer Res. 1987 Feb 15;47(4):1174-8. Cancer Res. 1987. PMID: 3802098

4

Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinoma.

Kempf RA, Grunberg SM, Daniels JR, Skinner DG, Venturi CL, Spiegel R, Neri R, Greiner JM, Rudnick S, Mitchell MS. Kempf RA, et al. Among authors: mitchell ms. J Biol Response Mod. 1986 Feb;5(1):27-35. J Biol Response Mod. 1986. PMID: 3958753 Clinical Trial.

5

Phase II study of low dose cyclophosphamide and intravenous interleukin-2 in metastatic renal cancer.

Quan WD Jr, Dean GE, Lieskovsky G, Mitchell MS, Kempf RA. Quan WD Jr, et al. Among authors: mitchell ms. Invest New Drugs. 1994;12(1):35-9. doi: 10.1007/BF00873233. Invest New Drugs. 1994. PMID: 7960603 Clinical Trial.

6

Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration.

Muss HB, Costanzi JJ, Leavitt R, Williams RD, Kempf RA, Pollard R, Ozer H, Zekan PJ, Grunberg SM, Mitchell MS, et al. Muss HB, et al. Among authors: mitchell ms. J Clin Oncol. 1987 Feb;5(2):286-91. doi: 10.1200/JCO.1987.5.2.286. J Clin Oncol. 1987. PMID: 3543247 Clinical Trial.

7

Immunological effects of recombinant interferon-alpha 2 in cancer patients.

Hengst JC, Kempf RA, Kan-Mitchell J, Pham AT, Grunberg SM, Kortes VL, Mitchell MS. Hengst JC, et al. Among authors: mitchell ms. J Biol Response Mod. 1983;2(6):516-27. J Biol Response Mod. 1983. PMID: 6663321

8

Phase II study of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma.

Grunberg SM, Kempf RA, Itri LM, Venturi CL, Boswell WD Jr, Mitchell MS. Grunberg SM, et al. Among authors: mitchell ms. Cancer Treat Rep. 1985 Sep;69(9):1031-2. Cancer Treat Rep. 1985. PMID: 4028036 No abstract available.

9

Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer.

Spicer DV, Kelley A, Herman R, Dean G, Stevenson L, Mitchell MS. Spicer DV, et al. Among authors: mitchell ms. Cancer Immunol Immunother. 1992;34(6):424-6. doi: 10.1007/BF01741755. Cancer Immunol Immunother. 1992. PMID: 1532923 Free PMC article. Clinical Trial.

10

Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.

Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Mitchell MS, et al. Cancer Res. 1988 Oct 15;48(20):5883-93. Cancer Res. 1988. PMID: 3262416

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

261 results

Search Page

Filters